Researchers from Japan have uncovered direct evidence showing how ketamine exerts its rapid antidepressant effects in ...

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...

A new brain-imaging study has revealed how ketamine produces its fast antidepressant effects in people with treatment-resistant depression. Researchers tracked changes in a critical brain receptor ...

Researchers used a novel PET tracer to visualize how ketamine alters AMPA receptor distribution in the brains of patients ...

Major depressive disorder (MDD) is one of the leading causes of disability worldwide, and approximately 30% of patients develop treatment-resistant depression (TRD), a condition that does not respond ...

Researchers compared total plasma pTau217 with a brain-derived pTau217 assay to determine which better identifies Alzheimer’s disease–related amyloid and tau pathology. Brain-derived pTau217 showed ...

Major depressive disorder (MDD) is a major global health problem and one of the leading causes of disability. About 30% of people diagnosed with ...

Titled "The Potential of Fasting and Diet in the Future of Medicine" Dr. Stacey's TEDx talk explores the frontier science of brain energy metabolism, how the brain's high demand for fuel and its ...

MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces ...

For people antidepressants can’t help, ketamine changes the brain in ways we can now see In A Nutshell For the first time, researchers used a specialized brain scan to watch how ketamine alters a key ...

Telix Pharmaceuticals focuses on radiopharmaceuticals for the diagnosis and treatment of cancer.